Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2017, Article ID 5905173, 10 pages
https://doi.org/10.1155/2017/5905173
Research Article

Prognostic Value of Metastatic Tumoral Caveolin-1 Expression in Patients with Resected Gastric Cancer

1Division of Oncology, Department of Internal Medicine, The Catholic University of Korea, Seoul, Republic of Korea
2Department of Pathology, Soonchunhyang Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Republic of Korea
3Department of Hospital Pathology, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu-si, Republic of Korea
4Department of General Surgery, The Catholic University of Korea, Seoul, Republic of Korea
5Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

Correspondence should be addressed to Yoon Ho Ko; rk.ca.cilohtac@ohnooyok

Received 24 April 2017; Revised 8 June 2017; Accepted 15 June 2017; Published 30 July 2017

Academic Editor: Nicola Silvestris

Copyright © 2017 Der Sheng Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. Caveolin-1 (Cav-1), as the main component of caveolae, has complex roles in tumourigenesis in human malignancies. We investigated Cav-1 in primary and metastatic tumor cells of gastric cancer (GC) and its association with clinical outcomes. Methods. We retrieved 145 cases of GC who had undergone curative gastrectomy. The expression levels of Cav-1 was evaluated by immunohistochemistry, and its association with clinicopathological parameters and patient survival was analyzed. Results. High expression of Cav-1 protein of the GC in the stomach and metastatic lymph node was 12.4% (18/145) and 16.5% (15/91). In the multivariate analysis, tumoral Cav-1 protein in metastatic lymph node showed prognostic significance for relapse-free survival (RFS, HR, 3.934; 95% CI, 1.882–8.224; ) and cancer-specific survival outcome (CSS, HR, 2.681; 95% CI, 1.613–8.623; ). Among the GCs with metastatic lymph node, it remained as a strong indicator of poor prognosis for RFS (HR, 3.136; 95% CI, 1.444–6.810; ) and CSS (HR, 2.509; 95% CI, 1.078–5.837; ). Conclusion. High expression of tumoral Cav-1 protein in metastatic lymph node is associated with unfavorable prognosis of curative resected GC, indicating the potential of novel prognostic markers.